1. Home
  2. ICO Base
  3. Dermavir


Drugs & Healthcare


Dermavir is a Dendritic Cell-Targeting Therapeutic Vaccine Technology Platform.


Therapeutic Vaccine for treatment of HIV, referred to as “DermaVir”, is effective in boosting immune response which kills HIV-infected cells. Human clinical trials have demonstrated vaccine is capable of killing HIV-infected cells. DermaVir has a safety profile similar to vaccines used in healthy adults and children. DermaVir can also be a co-treatment option if administered with antiretroviral therapy.


Pre-sale start date 30 Mar 2018
Pre-sale end date 15 May 2018
Pre-sale token supply 9,000,000
Token Sale
ICO start date 15 May 2018
ICO end date 30 May 2018
ICO token supply 1,000,000
ICO Platform 3
Registration Country Hungary
Registration Year 1988
Token details
Ticker GIC
Type Utility-token
Additional Token Emission No
Accepted Currencies


Bonus Program

Presale 1st stage - 30% discount 
Presale 2nd stage - 20% discount
Presale 3rd stage - 10% discount

Token distribution

66% - ICO

3% - Bounty

21% - future sell

Funds allocation

15% - FDA Documentation
19% - Vaccines Design Team
19% - Salaries
4% - Experts fees
4% - Consultation fees
6% - Company Operations
4% - Legal
12% - Research
2% - Equipment
3% - Travel
6% - Patenting
6% - Reserve


Type of scores
Hype score Low Active

Team members

Advisor Member of 18 ICOs
Chief Operations Officer Member of this ICO only
Chief Executive Officer Member of this ICO only

Funding Rounds

Rating Review and Analytics

Investment rating Info NA
Hype score Info Low
Risk score Info NA
Dermavir ICO Contacts


Start ICO 15 May 2018
End ICO 30 May 2018
Token GIC
Price 1 GIC = 1 USD
Product Type Technology
MVP Beta
Registration Country Hungary
Whitepaper View
Dermavir rating widget
Rating Get this widget
ICOs that might interest you

Status TBA
Hype score High
Risk score Medium
Investment rating Risky

Status TBA
Hype score Medium
Risk score Low
Investment rating Stable

Status TBA
Hype score High
Risk score Medium
Investment rating Stable+

Status Ongoing
Hype score Medium
Risk score Medium
Investment rating Stable+